ArticleFrontiers in microbiology2022
To the Gut Microbiome and Beyond: The Brain-First or Body-First Hypothesis in Parkinson's Disease.
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Temporal onset of non-motor symptoms and the body-first/brain-first dichotomy in Parkinson's disease: a cross-sectional single center experience.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Exploring the effects of faecal microbiota transplantation on cognitive function: A review of clinical trials.Brain, behavior, & immunity - health · 2025Review
- Review
- Exploring efficient and effective mammalian models for Alzheimer's disease.Frontiers in aging neuroscience · 2025Review
- Supplementation of the Probiotic LLH135 Reduces Oxidative Stress in a Model of Hemiparkinsonism.Behavioural neurology · 2025Article
- Gut microbiota and Parkinson's disease: potential links and the role of fecal microbiota transplantation.Frontiers in aging neuroscience · 2024Review
- The Impact of microRNAs on Mitochondrial Function and Immunity: Relevance to Parkinson's Disease.Biomedicines · 2023Review
- Neuroprotective and Immunomodulatory Effects of Probiotics in a Rat Model of Parkinson's Disease.Neurotoxicity research · 2023Article
- The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson's disease.Frontiers in neurology · 2023Review
- Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson's Disease.Journal of Parkinson's disease · 2023Review
- Impact of Dietary Arachidonic Acid on Gut Microbiota Composition and Gut-Brain Axis in Male BALB/C Mice.Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is continued debate regarding Parkinson's disease etiology and whether it originates in the brain or begins in the gut. Recently, evidence has been provided for both, with Parkinson's disease onset presenting as either a "body-first" or "brain-first" progression. Most research indicates those with Parkinson's disease have an altered gut microbiome compared to controls. However, some studies do not report gut microbiome differences, potentially due to the brain or body-first progression type. Based on the etiology of each proposed progression, individuals with the body-first progression may exhibit altered gut microbiomes, i.e., where short-chain fatty acid producing bacteria are reduced, while the brain-first progression may not. Future microbiome research should consider this hypothesis and investigate whether gut microbiome differences exist between each type of progression. This may further elucidate the impact of the gut microbiome in Parkinson's disease and show how it may not be homogenous across individuals with Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.